Detailed introduction and clinical treatment application scope of Odyxibat (Beierwei)

Odevixibat (Odevixibat) is an oral small molecule selective bile acid transporter (IBAT) inhibitor. It is mainly used to treat rare genetic liver diseases in children with cholestasis, such as familial cholestatic liver disease (PFIC). This drug reduces bile acid reabsorption by inhibiting the activity of the small intestinal ileal bile acid transporter, thereby reducing serum bile acid levels and reducing the degree of itching and liver damage.

In clinical studies, odexibat has shown significant efficacy. Multiple trials have shown that after taking odexibat, PFIC patients' pruritus symptoms were significantly relieved, and serum bile acid levels were effectively controlled. Compared with traditional therapies, the oral administration method and targeted mechanism of action of odexibat have significantly improved the quality of life of patients, especially children, who are more comfortable during sleep and daily activities.

The indications for odexibat include primary cholestatic liver disease in children caused by genetic defects. In addition to PFIC, researchers are also exploring its potential application in other cholestasis-related diseases, such as cholestatic cirrhosis and certain drug-induced cholestatic diseases. When using it, clinicians will make individual dosage adjustments based on the patient's bile acid level, liver function and age to ensure efficacy and safety.

Overall, odexibat provides a new treatment for rare childhood liver diseases by targeting a key link in the bile acid cycle. Its oral dosage form is convenient for long-term use and has mild side effects, providing scientific basis for improving cholestasis symptoms and liver function. With the accumulation of more clinical data in the future, the application scope of odexibat in cholestasis-related diseases may be further expanded, bringing treatment hope to more patients.

Reference link:https://www.drugs.com